648 related articles for article (PubMed ID: 30091999)
1. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
[TBL] [Abstract][Full Text] [Related]
2. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
3. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
4. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Müller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL
Blood; 2012 Feb; 119(6):1501-10. PubMed ID: 22184410
[TBL] [Abstract][Full Text] [Related]
7. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
8. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
[TBL] [Abstract][Full Text] [Related]
9. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
[TBL] [Abstract][Full Text] [Related]
11. The biology of normal and neoplastic stem cells in CML.
Eaves C; Udomsakdi C; Cashman J; Barnett M; Eaves A
Leuk Lymphoma; 1993; 11 Suppl 1():245-53. PubMed ID: 8251904
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients.
Levescot A; Flamant S; Basbous S; Jacomet F; Féraud O; Anne Bourgeois E; Bonnet ML; Giraud C; Roy L; Barra A; Chomel JC; Turhan A; Guilhot F; Girard JP; Gombert JM; Herbelin A
Cancer Res; 2014 May; 74(10):2669-76. PubMed ID: 24675360
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation.
Bhatia R; Munthe HA; Williams AD; Zhang F; Forman SJ; Slovak ML
Exp Hematol; 2000 Dec; 28(12):1401-12. PubMed ID: 11146162
[TBL] [Abstract][Full Text] [Related]
14. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
[TBL] [Abstract][Full Text] [Related]
15. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
[TBL] [Abstract][Full Text] [Related]
16. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Chu S; McDonald T; Bhatia R
Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
18. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
[TBL] [Abstract][Full Text] [Related]
19. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
